ADARx Pharmaceuticals, Inc. (ADRX)
17.63
-0.05
(-0.28%)
USD |
NASDAQ |
Oct 23, 16:00
17.80
+0.17
(+0.96%)
After-Hours: 20:00
ADARx Pharmaceuticals Net Income (Quarterly) : -25.76M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -25.76M |
| March 31, 2026 | -22.67M |
| Date | Value |
|---|---|
| June 30, 2025 | -18.09M |
| March 31, 2025 | -15.55M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.746M |
| Total Expenses (Quarterly) | 26.50M |
| EPS Diluted (Quarterly) | -0.2412 |
| Enterprise Value | 1.820B |
| Gross Profit Margin (Quarterly) | 1.47% |
| Profit Margin (Quarterly) | -3.45K% |
| Earnings Yield | -4.36% |
| Normalized Earnings Yield | -4.358 |